Heise takes up the question that arrives with every wave of health apps: can software treat depression? The honest answer, after a decade of trials and one of the world's more formal reimbursement experiments, is a qualified yes — for specific products, specific severities, and specific amounts of human support.
Start with what is established. Cognitive behavioural therapy works, and its core mechanisms are unusually well suited to delivery by a structured program: psychoeducation, thought records, behavioural activation, sleep hygiene, graded exposure. A well-built app can teach those skills, prompt practice between sessions, and collect symptom data that a clinician would otherwise see only monthly. Randomised trials of several prescription-grade programs — Germany's reimbursable DiGA catalogue is the clearest public register of them — have shown statistically significant improvements in depressive symptoms versus waiting lists or treatment as usual.
The argument starts with the size of those effects. Statistical significance and clinical meaningfulness are different things, and the average effect in trials of app-based interventions is modest: real, measurable, and generally smaller than what a course of face-to-face psychotherapy produces. That is not a scandal; it is what you would expect from a lower-intensity intervention. The mistake is presenting a modest effect as a replacement for a larger one, and the opposite mistake is dismissing it because it is not larger. For someone on a six-month waiting list, a modest effect available now is worth more than a large effect available in the spring.
Then comes the question of who is actually using it. Trial populations are motivated volunteers recruited by researchers. Real users download an app, use it for eleven days, and stop. Retention is the quiet killer of digital health, and the products that survive it are usually the ones attached to a human — a therapist who sees the dashboard, a coach who calls, a prescribing physician who asks about it at the next appointment. Evidence increasingly clusters around blended care rather than pure self-help, which is a less exciting story than an app instead of a therapist, and considerably more accurate.
Safety deserves the same candour. Apps can carry people through mild to moderate symptoms; severe depression, suicidality, psychosis and bipolar disorder need clinical management, and a program that fails to screen those users out is not neutral, it is dangerous. The regulatory pathway matters here: Germany's requirement of a positive care effect, demonstrated in trials and maintained with real-world data, is a stronger bar than app-store availability, and it is the reason a reimbursable product can be discussed as medicine at all.
Two practical caveats. Digital therapeutics are data businesses as much as clinical ones — symptom logs, sleep patterns, sometimes location — and a depression app that monetises attention has a conflict of interest in the treatment it delivers. And access is not the same as uptake: a prescription that no general practitioner offers, that no patient knows exists, changes nothing. Reimbursement without workflow integration is a subsidy for a product nobody uses.
Where this leaves the field: app-based programs are a legitimate, evidence-supported, low-intensity option for mild to moderate depression, best used as part of a stepped-care model with humans in the loop, not a queue-jumping substitute for specialist treatment. The interesting question for the next few years is not whether software can help — it can — but whether health systems can wire it into care in a way that reaches the people on the waiting list rather than the people who were going to recover anyway.
